Hereditary angioedema Blood-derived<unk>  is effective but does carry the risk associated with the use of any human blood product. Cinryze, a pharmaceutical-grade<unk> , was approved for the use of HAE in 2008 in the US after having been available in Europe for decades. It is a highly purified, pasteurized and nanofiltered plasma-derived<unk>  esterase<unk>  product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. A recombinant<unk>  obtained from the milk of transgenic rabbits, conestat alfa (trade name Ruconest), is approved for the treatment of acute HAE attacks in adults. While<unk>  therapy has been used acutely for more than 35 years in Europe in patients with<unk>  deficiency, new methods of treating acute attacks have emerged: a plasma kallikrein<unk>  and the bradykinin receptor antagonist icatibant. Other products also have been introduced including plasma-derived products such as Berinert and Haegarda. For other conditions The activation of the complement cascade can cause damage to cells, therefore the inhibition of the complement cascade can work as a medicine in certain conditions. When someone has a heart attack, for instance, the lack of oxygen in heart cells causes necrosis in heart cells: Dying heart cells spill their contents in the extracellular environment, which triggers the complement cascade. Activation of the complement cascade attracts phagocytes that leak peroxide and other reagents, which may increase the damage for the surviving heart cells. Inhibition of the complement cascade can decrease this damage. Synthesis<unk>  is contained in the human blood; it can, therefore, be isolated from donated blood. Risks of infectious disease transmission (viruses, prions, etc.) and relative expense of isolation prevented widespread use. It is also possible to produce it by recombinant technology, but Escherichia coli (the most commonly used organism for this purpose) lacks the eukaryotic ability to glycosylate proteins; as<unk>  is particularly heavily glycosylated, this sialylated recombinant form would have a short circulatory life (the carbohydrates are not relevant to the<unk>  function). Therefore,<unk>  has also been produced in glycosylated form using transgenic rabbits. This form of recombinant<unk>  also has been given orphan drug status for delayed graft function following organ transplantation and for capillary leakage syndrome.
C1-inhibitor
Complement component 3
C3a 
Complement component 4
Complement component 5a
Β-Thromboglobulin
Antileukotriene
Α-Hederin